Trexquant Investment LP Takes $1.16 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)

Trexquant Investment LP purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 150,022 shares of the biotechnology company’s stock, valued at approximately $1,160,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC boosted its holdings in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the period. GAMMA Investing LLC lifted its position in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in REGENXBIO in the 4th quarter valued at about $54,000. EntryPoint Capital LLC bought a new stake in REGENXBIO in the 4th quarter valued at about $97,000. Finally, Teacher Retirement System of Texas lifted its position in REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,088 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Price Performance

NASDAQ RGNX opened at $5.41 on Friday. The company’s 50 day simple moving average is $7.05 and its 200 day simple moving average is $8.32. REGENXBIO Inc. has a 12 month low of $5.04 and a 12 month high of $19.38. The company has a market capitalization of $270.97 million, a P/E ratio of -1.08 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. On average, analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on RGNX shares. Raymond James started coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. Finally, StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.78.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.